Cormorant Asset Management, LP Cyma Bay Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $25.9 Million - $50.2 Million	-2,050,000 Reduced 53.25%	1,800,000 $42.5 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $543,000 - $881,000	50,000 Added 1.32%	3,850,000 $57.4 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $18.9 Million - $27.7 Million	2,528,571 Added 198.88%	3,800,000 $41.6 Million
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $7.48 Million - $12.2 Million	1,271,429 New	1,271,429 $11.1 Million
Q4 2017 Feb 14, 2018	SELL	$7.67 - $9.31 $3.84 Million - $4.66 Million	-500,000 Closed	0 $0

Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $2.98 Million - $4.13 Million	500,000	500,000 $4.03 Million

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.